Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2018-2030F, by Region, Type, Application/End-Use
- Published Date: 2024-08-17
- Report ID: 158808
- Pages: 150
-
Format:
Summary
The global Chemotherapy Induced Peripheral Neuropathy Treatment market was estimated at xxx Million USD in 2021 and will reach xxx Million USD in 2030 with CAGR xx% during 2021-2030. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
The report includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.
Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
APX-3330
BR-297
Cannabidiol
Dimiracetam
Others
Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
Achelios Therapeutics Inc
Advinus Therapeutics Ltd
Apollo Endosurgery Inc
Aptinyx Inc
Asahi Kasei Pharma Corp
Can-Fite BioPharma Ltd
Celgene Corp
DermaXon LLC
Eisai
Immune Pharmaceuticals Inc
INSYS Therapeutics Inc
Kineta Inc
KPI Therapeutics Inc
Krenitsky Pharmaceuticals Inc
MAKScientific LLC
Metys Pharmaceuticals AG
Midatech Pharma US Inc
Mundipharma International Ltd
Nemus Bioscience Inc
Neurocentrx Pharma Ltd
Panacea Pharmaceuticals Inc
PeriphaGen Inc
PharmatrophiX Inc
PledPharma AB
Sova Pharmaceuticals Inc
Virobay Inc
WEX Pharmaceuticals Inc
Based on Application, the report describes major application share of regional market. Application mentioned as follows:
Clinic
Hospital
Others
Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
Asia-Pacific
North America
Europe
South America
Middle East & Africa
Table of Contents
1 MARKET OVERVIEW
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment of Research
1.1.1 Definition
1.1.2 Specifications of Chemotherapy Induced Peripheral Neuropathy Treatment
1.2 Market Segment by Product
1.2.1 Segment Overview
1.2.1.1 APX-3330 Overview
1.2.1.2 BR-297 Overview
1.2.1.3 Cannabidiol Overview
1.2.1.4 Dimiracetam Overview
1.2.1.5 Others Overview
1.2.2 Segment Market Date
1.3 Market Segment by Application/End-Use
1.3.1 Segment Overview
1.3.1.1 Clinic
1.3.1.2 Hospital
1.3.1.3 Others
1.3.2 Segment Market Date
1.4 Global & Major Region Market Size and Forecast
2 DEPLOYMENT ENVIRONMENT
2.1 Industry Chain Overview
2.1.1 Industry Chain
2.1.2 Manufacturing Process
2.2 Market Environment
2.2.1 SWOT
2.2.2 Dynamics
2.3 Marketing Channel
3 MARKET SEGMENTATION BY PRODUCT TYPE
3.1 Market Size by Product Type 2018-2023
3.1.1 APX-3330 Market Size 2018-2023
3.1.1.1 Global APX-3330 Market Size and Growth Rate 2018-2023
3.1.1.2 Global APX-3330 Market Size by Region 2018-2023
3.1.2 BR-297 Market Size 2018-2023
3.1.2.1 Global BR-297 Market Size and Growth Rate 2018-2023
3.1.2.2 Global BR-297 Market Size by Region 2018-2023
3.1.3 Cannabidiol Market Size 2018-2023
3.1.3.1 Global Cannabidiol Market Size and Growth Rate 2018-2023
3.1.3.2 Global Cannabidiol Market Size by Region 2018-2023
3.1.4 Dimiracetam Market Size 2018-2023
3.1.4.1 Global Dimiracetam Market Size and Growth Rate 2018-2023
3.1.4.2 Global Dimiracetam Market Size by Region 2018-2023
3.1.5 Others Market Size 2018-2023
3.1.5.1 Global Others Market Size and Growth Rate 2018-2023
3.1.5.2 Global Others Market Size by Region 2018-2023
3.2 Market Estimates and Forecasts by Product Type 2024E-2030F
3.2.1 APX-3330 Market Estimates and Forecasts 2024E-2030F
3.2.1.1 Global APX-3330 Market Forecasts and Growth Rate 2024E-2030F
3.2.1.2 Global APX-3330 Market Estimates and Forecasts by Region 2024E-2030F
3.2.2 BR-297 Market Estimates and Forecasts 2024E-2030F
3.2.2.1 Global BR-297 Market Forecasts and Growth Rate 2024E-2030F
3.2.2.2 Global BR-297 Market Estimates and Forecasts by Region 2024E-2030F
3.2.3 Cannabidiol Market Estimates and Forecasts 2024E-2030F
3.2.3.1 Global Cannabidiol Market Forecasts and Growth Rate 2024E-2030F
3.2.3.2 Global Cannabidiol Market Estimates and Forecasts by Region 2024E-2030F
3.2.4 Dimiracetam Market Estimates and Forecasts 2024E-2030F
3.2.4.1 Global Dimiracetam Market Forecasts and Growth Rate 2024E-2030F
3.2.4.2 Global Dimiracetam Market Estimates and Forecasts by Region 2024E-2030F
3.2.5 Others Market Estimates and Forecasts 2024E-2030F
3.2.5.1 Global Others Market Forecasts and Growth Rate 2024E-2030F
3.2.5.2 Global Others Market Estimates and Forecasts by Region 2024E-2030F
4 MARKET SEGMENTATION BY APPLICATION/END-USE
4.1 Market Size by Application/End-Use 2018-2023
4.1.1 Clinic Market Size 2018-2023
4.1.1.1 Global Clinic Market Size and Growth Rate 2018-2023
4.1.1.2 Global Clinic Market Size by Region 2018-2023
4.1.2 Hospital Market Size 2018-2023
4.1.2.1 Global Hospital Market Size and Growth Rate 2018-2023
4.1.2.2 Global Hospital Market Size by Region 2018-2023
4.1.3 Others Market Size 2018-2023
4.1.3.1 Global Others Market Size and Growth Rate 2018-2023
4.1.3.2 Global Others Market Size by Region 2018-2023
4.2 Market Estimates and Forecasts by Application/End-Use 2024E-2030F
4.2.1 Clinic Market Estimates and Forecasts 2024E-2030F
4.2.1.1 Global Clinic Market Forecasts and Growth Rate 2024E-2030F
4.2.1.2 Global Clinic Market Estimates and Forecasts by Region 2024E-2030F
4.2.2 Hospital Market Estimates and Forecasts 2024E-2030F
4.2.2.1 Global Hospital Market Forecasts and Growth Rate 2024E-2030F
4.2.2.2 Global Hospital Market Estimates and Forecasts by Region 2024E-2030F
4.2.3 Others Market Estimates and Forecasts 2024E-2030F
4.2.3.1 Global Others Market Forecasts and Growth Rate 2024E-2030F
4.2.3.2 Global Others Market Estimates and Forecasts by Region 2024E-2030F
5 MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
5.1 Market Size by Distribution Channel 2018-2023
5.1. E-Commerce Market Size 2018-2023
5.1.1.1 Global E-Commerce Market Size and Growth Rate 2018-2023
5.1.1.2 Global E-Commerce Market Size by Region 2018-2023
5.1.2 Traditional Channel Market Size 2018-2023
5.1.2.1 Global Traditional Channel Market Size and Growth Rate 2018-2023
5.1.2.2 Global Traditional Channel Market Size by Region 2018-2023
5.2 Market Estimates and Forecasts by Distribution Channel 2024E-2030F
5.2.1 E-Commerce Market Estimates and Forecasts 2024E-2030F
5.2.1.1 Global E-Commerce Market Forecasts and Growth Rate 2024E-2030F
5.2.1.2 Global E-Commerce Market Estimates and Forecasts by Region 2024E-2030F
5.2.2 Traditional Channel Market Estimates and Forecasts 2024E-2030F
5.2.2.1 Global Traditional Channel Market Forecasts and Growth Rate 2024E-2030F
5.2.2.2 Global Traditional Channel Market Estimates and Forecasts by Region 2024E-2030F
6 MARKET SEGMENTATION by Country/COUNTRY
6.1 Market Size by Region 2018-2023
6.1.1 Asia-Pacific Market Size 2018-2023
6.1.1.1 Asia-Pacific Market Size and Growth Rate 2018-2023
6.1.1.2 Asia-Pacific Market Size by Country 2018-2023
6.1.1.3 Asia-Pacific Market Size by Product Type 2018-2023
6.1.1.4 Asia-Pacific Market Size by Application/End-Use 2018-2023
6.1.1.5 Asia-Pacific Market Size by Distribution Channel 2018-2023
6.1.2 Europe Market Size 2018-2023
6.1.2.1 Europe Market Size and Growth Rate 2018-2023
6.1.2.2 Europe Market Size by Country 2018-2023
6.1.2.3 Europe Market Size by Product Type 2018-2023
6.1.2.4 Europe Market Size by Application/End-Use 2018-2023
6.1.2.5 Europe Market Size by Distribution Channel 2018-2023
6.1.3 North America Market Size 2018-2023
6.1.3.1 North America Market Size and Growth Rate 2018-2023
6.1.3.2 North America Market Size by Country 2018-2023
6.1.3.3 North America Market Size by Product Type 2018-2023
6.1.3.4 North America Market Size by Application/End-Use 2018-2023
6.1.3.5 North America Market Size by Distribution Channel 2018-2023
6.1.4 South America Market Size 2018-2023
6.1.4.1 South America Market Size and Growth Rate 2018-2023
6.1.4.2 South America Market Size by Country 2018-2023
6.1.4.3 South America Market Size by Product Type 2018-2023
6.1.4.4 South America Market Size by Application/End-Use 2018-2023
6.1.4.5 South America Market Size by Distribution Channel 2018-2023
6.1.5 Middle East & Africa Market Size 2018-2023
6.1.5.1 Middle East & Africa Market Size and Growth Rate 2018-2023
6.1.5.2 Middle East & Africa Market Size by Country 2018-2023
6.1.5.3 Middle East & Africa Market Size by Product Type 2018-2023
6.1.5.4 Middle East & Africa Market Size by Application/End-Use 2018-2023
6.1.5.5 Middle East & Africa Market Size by Distribution Channel 2018-2023
6.2 Market Estimates and Forecasts by Region 2024E-2030F
6.2.1 Asia-Pacific Market Estimates and Forecasts 2024E-2030F
6.2.1.1 Asia-Pacific Market Forecast and Growth Rate 2024E-2030F
6.2.1.2 Asia-Pacific Market Estimates & Forecast by Country 2024E-2030F
6.2.1.3 Asia-Pacific Market Estimates & Forecast by Product Type 2024E-2030F
6.2.1.4 Asia-Pacific Market Estimates & Forecast by Application/End-Use 2024E-2030F
6.2.1.5 Asia-Pacific Market Estimates & Forecast by Distribution Channel 2024E-2030F
6.2.2 Europe Market Estimates and Forecasts 2024E-2030F
6.2.2.1 Europe Market Forecast and Growth Rate 2024E-2030F
6.2.2.2 Europe Market Estimates & Forecast by Country 2024E-2030F
6.2.2.3 Europe Market Estimates & Forecast by Product Type 2024E-2030F
6.2.2.4 Europe Market Estimates & Forecast by Application/End-Use 2024E-2030F
6.2.2.5 Europe Market Estimates & Forecast by Distribution Channel 2024E-2030F
6.2.3 North America Market Estimates and Forecasts 2024E-2030F
6.2.3.1 North America Market Forecast and Growth Rate 2024E-2030F
6.2.3.2 North America Market Estimates & Forecast by Country 2024E-2030F
6.2.3.3 North America Market Estimates & Forecast by Product Type 2024E-2030F
6.2.3.4 North America Market Estimates & Forecast by Application/End-Use 2024E-2030F
6.2.3.5 North America Market Estimates & Forecast by Distribution Channel 2024E-2030F
6.2.4 South America Market Estimates and Forecasts 2024E-2030F
6.2.4.1 South America Market Forecast and Growth Rate 2024E-2030F
6.2.4.2 South America Market Estimates & Forecast by Country 2024E-2030F
6.2.4.3 South America Market Estimates & Forecast by Product Type 2024E-2030F
6.2.4.4 South America Market Estimates & Forecast by Application/End-Use 2024E-2030F
6.2.4.5 South America Market Estimates & Forecast by Distribution Channel 2024E-2030F
6.2.5 Middle East & Africa Market Estimates and Forecasts 2024E-2030F
6.2.5.1 Middle East & Africa Market Forecast and Growth Rate 2024E-2030F
6.2.5.2 Middle East & Africa Market Estimates & Forecast by Country 2024E-2030F
6.2.5.3 Middle East & Africa Market Estimates & Forecast by Product Type 2024E-2030F
6.2.5.4 Middle East & Africa Market Estimates & Forecast by Application/End-Use 2024E-2030F
6.2.5.5 Middle East & Africa Market Estimates & Forecast by Distribution Channel 2024E-2030F
7 MARKET COMPETITIVE
7.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competition
7.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Companies
7.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share
7.2 Market Concentration
7.3 Mergers & Acquisition Overview
7.4 Price & Factors
7.4.1 Price Overview
7.4.2 Factors
8 MAJOR PLAYERS OVERVIEW
8.1 Achelios Therapeutics Inc
8.1.1 Achelios Therapeutics Inc Company Profile
8.1.2 Achelios Therapeutics Inc Product Portfolio
8.1.3 Achelios Therapeutics Inc Business Performance
8.1.4 Achelios Therapeutics Inc Development Overview
8.2 Advinus Therapeutics Ltd
8.2.1 Advinus Therapeutics Ltd Company Profile
8.2.2 Advinus Therapeutics Ltd Product Portfolio
8.2.3 Advinus Therapeutics Ltd Business Performance
8.2.4 Advinus Therapeutics Ltd Development Overview
8.3 Apollo Endosurgery Inc
8.3.1 Apollo Endosurgery Inc Company Profile
8.3.2 Apollo Endosurgery Inc Product Portfolio
8.3.3 Apollo Endosurgery Inc Business Performance
8.3.4 Apollo Endosurgery Inc Development Overview
8.4 Aptinyx Inc
8.4.1 Aptinyx Inc Company Profile
8.4.2 Aptinyx Inc Product Portfolio
8.4.3 Aptinyx Inc Business Performance
8.4.4 Aptinyx Inc Development Overview
8.5 Asahi Kasei Pharma Corp
8.5.1 Asahi Kasei Pharma Corp Company Profile
8.5.2 Asahi Kasei Pharma Corp Product Portfolio
8.5.3 Asahi Kasei Pharma Corp Business Performance
8.5.4 Asahi Kasei Pharma Corp Development Overview
8.6 Can-Fite BioPharma Ltd
8.6.1 Can-Fite BioPharma Ltd Company Profile
8.6.2 Can-Fite BioPharma Ltd Product Portfolio
8.6.3 Can-Fite BioPharma Ltd Business Performance
8.6.4 Can-Fite BioPharma Ltd Development Overview
8.7 Celgene Corp
8.7.1 Celgene Corp Company Profile
8.7.2 Celgene Corp Product Portfolio
8.7.3 Celgene Corp Business Performance
8.7.4 Celgene Corp Development Overview
8.8 DermaXon LLC
8.8.1 DermaXon LLC Company Profile
8.8.2 DermaXon LLC Product Portfolio
8.8.3 DermaXon LLC Business Performance
8.8.4 DermaXon LLC Development Overview
8.9 Eisai
8.9.1 Eisai Company Profile
8.9.2 Eisai Product Portfolio
8.9.3 Eisai Business Performance
8.9.4 Eisai Development Overview
8.10 Immune Pharmaceuticals Inc
8.10.1 Immune Pharmaceuticals Inc Company Profile
8.10.2 Immune Pharmaceuticals Inc Product Portfolio
8.10.3 Immune Pharmaceuticals Inc Business Performance
8.10.4 Immune Pharmaceuticals Inc Development Overview
8.11 INSYS Therapeutics Inc
8.11.1 INSYS Therapeutics Inc Company Profile
8.11.2 INSYS Therapeutics Inc Product Portfolio
8.11.3 INSYS Therapeutics Inc Business Performance
8.11.4 INSYS Therapeutics Inc Development Overview
8.12 Kineta Inc
8.12.1 Kineta Inc Company Profile
8.12.2 Kineta Inc Product Portfolio
8.12.3 Kineta Inc Business Performance
8.12.4 Kineta Inc Development Overview
8.13 KPI Therapeutics Inc
8.13.1 KPI Therapeutics Inc Company Profile
8.13.2 KPI Therapeutics Inc Product Portfolio
8.13.3 KPI Therapeutics Inc Business Performance
8.13.4 KPI Therapeutics Inc Development Overview
8.14 Krenitsky Pharmaceuticals Inc
8.14.1 Krenitsky Pharmaceuticals Inc Company Profile
8.14.2 Krenitsky Pharmaceuticals Inc Product Portfolio
8.14.3 Krenitsky Pharmaceuticals Inc Business Performance
8.14.4 Krenitsky Pharmaceuticals Inc Development Overview
8.15 MAKScientific LLC
8.15.1 MAKScientific LLC Company Profile
8.15.2 MAKScientific LLC Product Portfolio
8.15.3 MAKScientific LLC Business Performance
8.15.4 MAKScientific LLC Development Overview
8.16 Metys Pharmaceuticals AG
8.16.1 Metys Pharmaceuticals AG Company Profile
8.16.2 Metys Pharmaceuticals AG Product Portfolio
8.16.3 Metys Pharmaceuticals AG Business Performance
8.16.4 Metys Pharmaceuticals AG Development Overview
8.17 Midatech Pharma US Inc
8.17.1 Midatech Pharma US Inc Company Profile
8.17.2 Midatech Pharma US Inc Product Portfolio
8.17.3 Midatech Pharma US Inc Business Performance
8.17.4 Midatech Pharma US Inc Development Overview
8.18 Mundipharma International Ltd
8.18.1 Mundipharma International Ltd Company Profile
8.18.2 Mundipharma International Ltd Product Portfolio
8.18.3 Mundipharma International Ltd Business Performance
8.18.4 Mundipharma International Ltd Development Overview
8.19 Nemus Bioscience Inc
8.19.1 Nemus Bioscience Inc Company Profile
8.19.2 Nemus Bioscience Inc Product Portfolio
8.19.3 Nemus Bioscience Inc Business Performance
8.19.4 Nemus Bioscience Inc Development Overview
8.20 Neurocentrx Pharma Ltd
8.20.1 Neurocentrx Pharma Ltd Company Profile
8.20.2 Neurocentrx Pharma Ltd Product Portfolio
8.20.3 Neurocentrx Pharma Ltd Business Performance
8.20.4 Neurocentrx Pharma Ltd Development Overview
8.21 Panacea Pharmaceuticals Inc
8.21.1 Panacea Pharmaceuticals Inc Company Profile
8.21.2 Panacea Pharmaceuticals Inc Product Portfolio
8.21.3 Panacea Pharmaceuticals Inc Business Performance
8.21.4 Panacea Pharmaceuticals Inc Development Overview
8.22 PeriphaGen Inc
8.22.1 PeriphaGen Inc Company Profile
8.22.2 PeriphaGen Inc Product Portfolio
8.22.3 PeriphaGen Inc Business Performance
8.22.4 PeriphaGen Inc Development Overview
8.23 PharmatrophiX Inc
8.23.1 PharmatrophiX Inc Company Profile
8.23.2 PharmatrophiX Inc Product Portfolio
8.23.3 PharmatrophiX Inc Business Performance
8.23.4 PharmatrophiX Inc Development Overview
8.24 PledPharma AB
8.24.1 PledPharma AB Company Profile
8.24.2 PledPharma AB Product Portfolio
8.24.3 PledPharma AB Business Performance
8.24.4 PledPharma AB Development Overview
8.25 Sova Pharmaceuticals Inc
8.25.1 Sova Pharmaceuticals Inc Company Profile
8.25.2 Sova Pharmaceuticals Inc Product Portfolio
8.25.3 Sova Pharmaceuticals Inc Business Performance
8.25.4 Sova Pharmaceuticals Inc Development Overview
8.26 Virobay Inc
8.26.1 Virobay Inc Company Profile
8.26.2 Virobay Inc Product Portfolio
8.26.3 Virobay Inc Business Performance
8.26.4 Virobay Inc Development Overview
8.27 WEX Pharmaceuticals Inc
8.27.1 WEX Pharmaceuticals Inc Company Profile
8.27.2 WEX Pharmaceuticals Inc Product Portfolio
8.27.3 WEX Pharmaceuticals Inc Business Performance
8.27.4 WEX Pharmaceuticals Inc Development Overview
9 MARKET LANDSCAPE
9.1 Five Forces Analysis
9.1.1 Threat of New Entrants
9.1.2 Bargaining Power of Buyers
9.1.3 Threat of Substitutes
9.1.4 Segment Rivalry
9.2 Market Factors
9.2.1 Drivers
9.2.2 Restrains
9.2.3 Opportunities
10 MARKET CONCLUSION
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
